Hikma Manages To Stay Flat In 2022 Despite Generics Pressures

Annual Results See Injectables And Brands Success Offsetting Struggling Generics Unit

 
• By Dave Wallace

As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.

Finger pushing down on scales, balancing piles of coins
Growing returns from injectables and brands are helping to balance downwards pressures on Hikma’s generics business • Source: Shutterstock

More from Earnings

More from Business